Dont Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI Two medical sector stocks are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list in…
Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? The consensus price target hints at a 33.9% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this…
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2024,…
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 14.94% and 0.86%, respectively, for the quarter ended December 2024. Do…
Collegium Pharmaceutical beats Q4 estimates, shares rise 6.3% By Investing.com Collegium Pharmaceutical beats Q4 estimates, shares rise 6.3%…
Collegium Pharmaceutical stock hits 52-week low at $28.75 By Investing.com Collegium Pharmaceutical stock hits 52-week low at $28.75…
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock? Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…